Biotech Values

[linhdtu]

ayup and Fgen roxa is included. i predict roxa will become a B$ drug in the china mkt with a record shortest time.

in the same NRDL for 2019 i also saw a chinese PDL1 drug priced at deep discount to Keytruda ~90% ??? good bye Keytruda in china

from what i can gather, azn&fgen have done excellent groundwork prepping for roxa. it seems to me the entire chinese medical profession, whether practitioners or academicians,is raring to go with respect to roxa. that is why imo neff chose peony yu for CMO.

in the US, i have been following Andy Phung MD a nephrologist who mentioned that roxa when approved will be the rare new tool in his toolbox that has been pretty bare since he graduated med school.